Evidence map›Paper›PMID 42859307›Full record

ArticleEndocrine2026

Association of miRNA-500 and AGE-RAGE axis in the development of thyroid cancer.

Nazia Shoaib, Rizwana Sanaullah Waraich, Hurtamina Khan, Syeda Zauraiz Sohail, Syeda Sumayya Tariq, Fadieleh Adnan Sohail

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nazia ShoaibDepartment of Biomedical & Biological Sciences, Sohail University, Karachi, Pakistan.
Rizwana Sanaullah WaraichDepartment of Biomedical & Biological Sciences, Sohail University, Karachi, Pakistan. rizwanas.waraich@sohailuniversity.edu.pk.ORCID https://orcid.org/0000-0002-5560-5053
Hurtamina KhanHead & Neck Surgery department, Jinnah Post Graduate Medical Centre, Jinnah Sindh Medical University, Karachi, Pakistan.
Syeda Zauraiz SohailDepartment of Cell and System Biology, University of Toronto St George, Toronto, Canada.
Syeda Sumayya TariqDepartment of Biomedical & Biological Sciences, Sohail University, Karachi, Pakistan.
Fadieleh Adnan SohailJinnah Medical & Dental College, Karachi, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide, thyroid cancer is 7th most prevalent cancer, with projections indicating further increases by 2035. Few studies indicate role of micro RNA and RAGE receptor in cancer development. We hypothesize that micro RNA 500 may be associated with thyroid cancer development by effecting the AGE-RAGE axis. For the first time this study reported that miRNA-500 expression was higher in serum of subjects with papillary thyroid carcinoma (PTC) as compared to healthy controls. Similarly, higher levels of Advanced glycation end Products (AGEs) were seen and positively associated with mi-RNA500, in serum of PTC patients. While comparing the cancer and normal tissue of PTC patients we found enhanced expression of miRNA-500, RAGE receptor gene and protein in cancer tissue. RAGE ligands including HMGB-1 and S-100 were also found elevated in PTC cancer tissue as compared to normal tissue. In human thyroid cancer cells overexpressing miRNA-500 showed enhanced NFkB expression and oxidative stress however, this effect was diminished after blocking RAGE, linking miRNA-500 and RAGE together in development of thyroid cancer. Protein-protein interaction (PPI) pathway analysis further suggested that miR-500 target genes are embedded within a broader inflammatory signaling framework relevant to thyroid cancer biology. Our results demonstrate the association of miRNA-500 with RAGE axis along with preliminary evidence of pharmacological modulation, in thyroid cancer.

Indexed as

Glycation End Products, AdvancedMicroRNAsReceptor for Advanced Glycation End ProductsThyroid NeoplasmsAdultCarcinoma, PapillaryCell Line, TumorFemaleHMGB1 ProteinHumansMaleMiddle AgedOxidative StressSignal TransductionThyroid Cancer, PapillaryGlycation End Products, AdvancedHMGB1 ProteinMicroRNAsReceptor for Advanced Glycation End ProductsHMGB-1miRNA-500; Advanced glycation end productsReceptor for advanced glycation end productsS-100Thyroid cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.